Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach (Q73979679)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

meta-analysis

0 references

title

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

main subject

hepatocellular carcinoma

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

C Cammà

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

M Giunta

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

A Craxì

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

publication date

1 April 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

593-602

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json

Rising incidence of hepatocellular carcinoma in the United States

8 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Long-term course of interferon-treated chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

The long-term course of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Inborn/outborn status and neonatal survival: a meta-analysis of non-randomized studies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Meta-analyses of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Randomized versus historical controls for clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Selection bias in observational and experimental studies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

HCV viraemia is more important than genotype as a predictor of response to interferon in sicily (Southern Italy)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Wild-type, but not mutant-type, p53 enhances nuclear accumulation of the NS3 protein of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Transcriptional repression of p53 promoter by hepatitis C virus core protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Activation of p53 tumor suppressor by hepatitis C virus core protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

Survey of hepatitis B virus co-infection in hepatitis C virus-infected patients suffering from chronic hepatitis and hepatocellular carcinoma in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900005-8

7 January 2021

10.1016/S0168-8278(01)00005-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11394661%20AND%20SRC:MED&resulttype=core&format=json